Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening

eLife

Volumn 5, Issue NOVEMBER2016, 2016, Pages

  Verissimo, Carla S ^a,b   Overmeer, René M ^a,b   Ponsioen, Bas ^a,b   Drost, Jarno ^a,b   Mertens, Sander ^a,b   Verlaan Klink, Ingrid ^a,b   Van Gerwen, Bastiaan ^c   Van Der Ven, Marieke ^c   Van De Wetering, Marc ^a,b   Egan, David A ^a   Bernards, René ^b,c   Clevers, Hans ^a,b   Bos, Johannes L ^a,b   Snippert, Hugo J ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Cancer Genomics Centre Netherlands   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AFATINIB; ALPELISIB; DACOMITINIB; LAPATINIB; NAVITOCLAX; SELUMETINIB; TRAMETINIB; VENETOCLAX; ANTINEOPLASTIC AGENT; MUTANT PROTEIN; RAS PROTEIN;

ALLELE; ARTICLE; CELL CYCLE ARREST; CELL DEATH; CELL VIABILITY ASSAY; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; CRISPR CAS SYSTEM; DRUG RELEASE; DRUG SCREENING; DRUG SENSITIVITY; FLOW CYTOMETRY; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSFECTION; GENOTYPE; HUMAN; IC50; NONHUMAN; ONCOGENE RAS; TIME LAPSE IMAGING; TUMOR GROWTH; TUMOR XENOGRAFT; ANTAGONISTS AND INHIBITORS; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; COLORECTAL NEOPLASMS; CYTOPLASM; DRUG EFFECTS; GENETIC RECOMBINATION; ISOLATION AND PURIFICATION; PRECLINICAL STUDY; PROCEDURES;

ANTINEOPLASTIC AGENTS; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; COLORECTAL NEOPLASMS; DRUG EVALUATION, PRECLINICAL; HUMANS; MUTANT PROTEINS; ORGANOIDS; RAS PROTEINS; RECOMBINATION, GENETIC;

EID: 85001075487     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.18489     Document Type: Article

References (35)

1. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. 2008. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology 26:1626–1634. doi: 10.1200/JCO.2007.14.7116, PMID: 18316791
2. Bartfeld S, Bayram T, van de Wetering M, Huch M, Begthel H, Kujala P, Vries R, Peters PJ, Clevers H. 2015. In vitro expansion of human gastric epithelial stem cells and their responses to bacterial infection. Gastroenterology 148:126–136. doi: 10.1053/j.gastro.2014.09.042, PMID: 25307862
3. Boj SF, Hwang CI, Baker LA, Chio II, Engle DD, Corbo V, Jager M, Ponz-Sarvise M, Tiriac H, Spector MS, Gracanin A, Oni T, Yu KH, van Boxtel R, Huch M, Rivera KD, Wilson JP, Feigin ME, Öhlund D, Handly-Santana A, et al. 2015. Organoid models of human and mouse ductal pancreatic cancer. Cell 160:324–338. doi: 10.1016/j.cell.2014.12.021, PMID: 25557080
4. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KY, Artis DR, et al. 2010. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467:596–599. doi: 10.1038/nature09454, PMID: 20823850
5. Bos JL. 1989. ras oncogenes in human cancer: a review. Cancer Research 49:4682–4689. PMID: 2547513
6. Centenera MM, Raj GV, Knudsen KE, Tilley WD, Butler LM. 2013. Ex vivo culture of human prostate tissue and drug development. Nature Reviews Urology 10:483–487. doi: 10.1038/nrurol.2013.126, PMID: 23752995
7. Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S. 2015. Combined BRAF and MEK inhibition with Dabrafenib and Trametinib in BRAF V600-Mutant colorectal cancer. Journal of Clinical Oncology 33:4023–4031. doi: 10.1200/JCO.2015.63.2471, PMID: 26392102
8. Corcoran RB, Cheng KA, Hata AN, Faber AC, Ebi H, Coffee EM, Greninger P, Brown RD, Godfrey JT, Cohoon TJ, Song Y, Lifshits E, Hung KE, Shioda T, Dias-Santagata D, Singh A, Settleman J, Benes CH, Mino-Kenudson M, Wong KK, et al. 2013. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 23:121–128. doi: 10.1016/j.ccr.2012.11.007, PMID: 23245996
9. Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. 2014. Drugging the undruggable RAS: Mission possible? Nature Reviews Drug Discovery 13:828–851. doi: 10.1038/nrd4389, PMID: 25323927
10. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. 2008. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. Journal of Clinical Oncology 26:5705–5712. doi: 10.1200/JCO.2008.18.0786, PMID: 19001320
11. Drost J, van Jaarsveld RH, Ponsioen B, Zimberlin C, van Boxtel R, Buijs A, Sachs N, Overmeer RM, Offerhaus GJ, Begthel H, Korving J, van de Wetering M, Schwank G, Logtenberg M, Cuppen E, Snippert HJ, Medema JP, Kops GJ, Clevers H. 2015. Sequential cancer mutations in cultured human intestinal stem cells. Nature 521:43–47. doi: 10.1038/nature14415, PMID: 25924068
12. Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora VK, Wongvipat J, Kossai M, Ramazanoglu S, Barboza LP, Di W, Cao Z, Zhang QF, Sirota I, Ran L, MacDonald TY, et al. 2014. Organoid cultures derived from patients with advanced prostate cancer. Cell 159:176–187. doi: 10.1016/j.cell.2014.08.016, PMID: 25201530
13. Gould SE, Junttila MR, de Sauvage FJ. 2015. Translational value of mouse models in oncology drug development. Nature Medicine 21:431–439. doi: 10.1038/nm.3853, PMID: 25951530
14. Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, et al. 2015. The consensus molecular subtypes of colorectal cancer. Nature Medicine 21: 1350–1356. doi: 10.1038/nm.3967, PMID: 26457759
15. Hata AN, Engelman JA, Faber AC. 2015. The BCL2 family: Key mediators of the apoptotic response to targeted anticancer therapeutics. Cancer Discovery 5:475–487. doi: 10.1158/2159-8290.CD-15-0011, PMID: 25895919
16. Hata AN, Yeo A, Faber AC, Lifshits E, Chen Z, Cheng KA, Walton Z, Sarosiek KA, Letai A, Heist RS, Mino- Kenudson M, Wong KK, Engelman JA. 2014. Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers. Cancer Research 74:3146–3156. doi: 10.1158/0008-5472.CAN-13-3728, PMID: 24675361
17. Huch M, Gehart H, van Boxtel R, Hamer K, Blokzijl F, Verstegen MM, Ellis E, van Wenum M, Fuchs SA, de Ligt J, van de Wetering M, Sasaki N, Boers SJ, Kemperman H, de Jonge J, Ijzermans JN, Nieuwenhuis EE, Hoekstra R, Strom S, Vries RR, et al. 2015. Long-term culture of genome-stable bipotent stem cells from adult human liver. Cell 160:299–312. doi: 10.1016/j.cell.2014.11.050, PMID: 25533785
18. Jin K, Teng L, Shen Y, He K, Xu Z, Li G. 2010. Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review. Clinical and Translational Oncology 12:473–480. doi: 10.1007/s12094-010-0540-6, PMID: 20615824
19. Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. 2008. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. New England Journal of Medicine 359:1757–1765. doi: 10.1056/NEJMoa0804385, PMID: 18946061
20. Karthaus WR, Iaquinta PJ, Drost J, Gracanin A, van Boxtel R, Wongvipat J, Dowling CM, Gao D, Begthel H, Sachs N, Vries RG, Cuppen E, Chen Y, Sawyers CL, Clevers HC. 2014. Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell 159:163–175. doi: 10.1016/j.cell.2014.08.017, PMID: 25201529
21. Miroddi M, Sterrantino C, Simonelli I, Ciminata G, Phillips RS, Calapai G. 2015. Risk of grade 3-4 diarrhea and mucositis in colorectal cancer patients receiving anti-EGFR monoclonal antibodies regimens: A meta-analysis of 18 randomized controlled clinical trials. Critical Reviews in Oncology/Hematology 96:355–371. doi: 10.1016/j.critrevonc.2015.06.004, PMID: 26160607
22. Misale S, Bozic I, Tong J, Peraza-Penton A, Lallo A, Baldi F, Lin KH, Truini M, Trusolino L, Bertotti A, Di Nicolantonio F, Nowak MA, Zhang L, Wood KC, Bardelli A. 2015. Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers. Nature Communications 6:8305. doi: 10.1038/ncomms9305,PMID: 26392303
23. Ryan MB, Der CJ, Wang-Gillam A, Cox AD. 2015. Targeting RAS-mutant cancers: Is ERK the Key? Trends in Cancer 1:183-–198. doi: 10.1016/j.trecan.2015.10.001
24. Sachs N, Clevers H. 2014. Organoid cultures for the analysis of cancer phenotypes. Current Opinion in Genetics & Development 24:68–73. doi: 10.1016/j.gde.2013.11.012, PMID: 24657539
25. Sato T, Stange DE, Ferrante M, Vries RG, Van Es JH, Van den Brink S, Van Houdt WJ, Pronk A, Van Gorp J, Siersema PD, Clevers H. 2011. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology 141:1762–1772. doi: 10.1053/j.gastro.2011.07.050, PMID: 21889923
26. Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, van Es JH, Abo A, Kujala P, Peters PJ, Clevers H. 2009. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459:262–265. doi: 10.1038/nature07935, PMID: 19329995
27. Shaner NC, Lambert GG, Chammas A, Ni Y, Cranfill PJ, Baird MA, Sell BR, Allen JR, Day RN, Israelsson M, Davidson MW, Wang J. 2013. A bright monomeric green fluorescent protein derived from Branchiostoma lanceolatum. Nature Methods 10:407–409. doi: 10.1038/nmeth.2413, PMID: 23524392
28. Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Smith LS, Gunn S, Smetzer L, Mays TA, Kaiser B, Wick MJ, Alvarez C, Cavazos A, Mangold GL, Patnaik A. 2012. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clinical Cancer Research 18:2316–2325. doi: 10.1158/1078-0432.CCR-11-2381, PMID: 22261800
29. Snippert HJ, Schepers AG, van Es JH, Simons BD, Clevers H. 2014. Biased competition between Lgr5 intestinal stem cells driven by oncogenic mutation induces clonal expansion. EMBO Reports 15:62–69. doi: 10.1002/embr.201337799, PMID: 24355609
30. Stephen AG, Esposito D, Bagni RK, McCormick F. 2014. Dragging ras back in the ring. Cancer Cell 25:272–281. doi: 10.1016/j.ccr.2014.02.017, PMID: 24651010
31. Sun C, Hobor S, Bertotti A, Zecchin D, Huang S, Galimi F, Cottino F, Prahallad A, Grernrum W, Tzani A, Schlicker A, Wessels LF, Smit EF, Thunnissen E, Halonen P, Lieftink C, Beijersbergen RL, Di Nicolantonio F, Bardelli A, Trusolino L, et al. 2014. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. Cell Reports 7:86–93. doi: 10.1016/j.celrep.2014.02.045, PMID: 24685132
32. Tan N, Wong M, Nannini MA, Hong R, Lee LB, Price S, Williams K, Savy PP, Yue P, Sampath D, Settleman J, Fairbrother WJ, Belmont LD. 2013. Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models. Molecular Cancer Therapeutics 12: 853–864. doi: 10.1158/1535-7163.MCT-12-0949, PMID: 23475955
33. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, Arcaroli JJ, Messersmith WA, Eckhardt SG. 2012. Patient-derived tumour xenografts as models for oncology drug development. Nature Reviews Clinical Oncology 9:338–350. doi: 10.1038/nrclinonc.2012.61, PMID: 22508028
34. van de Wetering M, Francies HE, Francis JM, Bounova G, Iorio F, Pronk A, van Houdt W, van Gorp J, Taylor- Weiner A, Kester L, McLaren-Douglas A, Blokker J, Jaksani S, Bartfeld S, Volckman R, van Sluis P, Li VS, Seepo S, Sekhar Pedamallu C, Cibulskis K, et al. 2015. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161:933–945. doi: 10.1016/j.cell.2015.03.053, PMID: 25957691
35. Wong VW, Stange DE, Page ME, Buczacki S, Wabik A, Itami S, van de Wetering M, Poulsom R, Wright NA, Trotter MW, Watt FM, Winton DJ, Clevers H, Jensen KB. 2012. Lrig1 controls intestinal stem-cell homeostasis by negative regulation of ErbB signalling. Nature Cell Biology 14:401–408. doi: 10.1038/ncb2464, PMID: 22388892